Skip Ribbon Commands
Skip to main content

The Holmium Platform

Watch the replay

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

The Holmium Platform

Featured products: QuiremScout™ Microspheres, QuiremSpheres™ Microspheres

Safety Analysis of Holmium-166 Microsphere Scout Dose Imaging During Radioembolisation Work-Up: A Cohort Study

Featured product: QuiremScout™ Microspheres

Holmium-166 Radioembolisation in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice

Featured product: QuiremSpheres™ Microspheres

Efficacy of Radioembolisation with 166 Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study

Featured product: QuiremSpheres™ Microspheres

Holmium-166 Radioembolisation in Patients with Unresectable, Chemorefractory Liver Metastases (HEPAR trial): A phase 1, Dose-Escalation Study

Featured product: QuiremSpheres™ Microspheres

First evidence for a dose-response relationship in patients treated with 166Ho-radioembolization: a prospective study

Featured product: QuiremSpheres™ Microspheres

Quality of life in patients with liver tumors treated with holmium‑166 radioembolization

Featured product: QuiremSpheres™ Microspheres

The superior predictive value of 166Ho-scout compared with 99mTc-macroaggregated albumin prior to 166Ho-microspheres radioembolization in patients with liver metastases

Featured product: QuiremScout™ Microspheres

Clinical experience of QuiremScout® in a 69-year-old female patient with intrahepatic cholangiocarcinoma (iCCA)

Featured product: QuiremScout™ Microspheres

Clinical use of QuiremScout® in a 55-year-old male patient with hepatocellular carcinoma (HCC)

Featured product: QuiremScout™ Microspheres

99mTc-MAA Overestimates the Absorbed Dose to the Lungs in Radioembolisation: A Quantitative Evaluation in Patients Treated with 166Ho Microspheres

Featured product: QuiremScout™ Microspheres

QuiremSpheres® treatment in 73-years old female HCC patient

Featured product: QuiremSpheres™ Microspheres

QuiremSpheres® treatment of a 61-year-old male patient with mCRC after right hepatectomy

Featured product: QuiremSpheres™ Microspheres

QuiremSpheres® treatment of a 47-year-old female patient with mCRC after multiple hepatic resections

Featured product: QuiremSpheres™ Microspheres

QuiremSpheres® treatment of a 77-year-old male patient with hepatocellular carcinoma

Featured product: QuiremScout™ Microspheres

QuiremSpheres® treatment of a 64-year-old male patient with hepatic metastatic rectal carcinoma

Featured product: QuiremSpheres™ Microspheres

See all clinical evidence

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public


For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.